PolyNovo Limited (ASX:PNV): FY26 Wound-Care Sales, Profit and Manufacturing Progress

Aditi Sarkar

12 November 2026 04:39 PM AEDT

PolyNovo Limited (ASX:PNV): FY26 Wound-Care Sales, Profit and Manufacturing Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo (ASX:PNV) reported FY26 total Revenue of AUD 150.0 million.
Commercial product sales increased 16.7% to AUD 138.4 million.
FY26 EBITDA reached AUD 12.1 million and net profit totalled AUD 7.3 million.
A new Manufacturing Facility was completed, with validation preceding the planned transition.

PolyNovo Limited (ASX:PNV) develops and commercialises NovoSorb synthetic polymer products used in the treatment of complex wounds, including burns and surgical applications. Its shares were quoted at AUD 0.898 on 12 November 2026, down 0.83% during the trading session. The company’s FY26 financial results, product rollout and manufacturing programme provide the current operating context. Commercial expansion and product registration activity remain separate from the question of how much revenue ultimately converts into reported profit.

NovoSorb Products and International Markets

PolyNovo (ASX:PNV) markets NovoSorb Biodegradable Temporising Matrix, or BTM, and NovoSorb MTX. These products address different wound-management applications and are marketed through an international commercial structure. The United States accounts for a material share of commercial revenue, while other markets contribute through established and developing sales channels. Uptake depends on clinician experience, approved product indications, access to hospitals and reimbursement arrangements. Each product also has its own regulatory position, meaning registration in one country cannot be assumed to permit sales in another.

FY26 Commercial Sales and Product Mix

In August 2026, PolyNovo (ASX:PNV) reported total revenue of AUD 150.0 million, an increase of 16.1%, and commercial sales of AUD 138.4 million, up 16.7%. NovoSorb BTM sales were AUD 125.8 million, while NovoSorb MTX sales reached AUD 12.6 million. United States commercial sales totalled AUD 102.1 million and sales elsewhere amounted to AUD 36.3 million. The differences between regional and product growth rates make product mix and geography important when interpreting overall revenue. Currency movements also affect the translation of overseas sales into Australian dollars.

Profit, Cash Flow and Manufacturing Capacity

PolyNovo (ASX:PNV) recorded EBITDA of AUD 12.1 million and net profit after tax of AUD 7.3 million for FY26. Net profit fell despite revenue growth, illustrating why sales increases and after-tax Earnings need to be evaluated separately. Operating Cash Flow reached AUD 23.1 million and free cash flow was AUD 9.4 million. The company completed construction of a new Port Melbourne manufacturing facility and was progressing validation work ahead of a planned transition in FY27. Completion of construction does not itself establish the timing or Volume of commercial production from the new site.

Registration and Clinical Development

PolyNovo (ASX:PNV) continued clinical evidence work and regulatory submissions relating to the NovoSorb platform. Its FY26 disclosures described registration progress in additional European and international jurisdictions, with other applications still in process. The company also discussed activity related to expanded applications and reimbursement. Approval and procurement pathways vary across healthcare systems, and product availability can depend on regulatory clearance and clinical adoption. Commercial sales figures do not independently establish the outcomes of ongoing studies or the likelihood of future approvals.

Risks and Near-Term Monitoring

Key operating considerations include manufacturing validation, quality controls, reimbursement conditions, product registration, clinical purchasing decisions and distribution capacity. PolyNovo (ASX:PNV) also faces foreign exchange exposure because international sales are reported in Australian dollars. Future announcements may clarify the pace of the manufacturing transition, hospital account expansion, changes in sales mix and the contribution of MTX to revenue. Investors can compare future operating cash flow with Investment requirements and assess whether reported profit follows the same trajectory as commercial sales.

Key Insights

PolyNovo (ASX:PNV) recorded increased commercial sales and positive FY26 operating cash flow, but a lower reported net profit. Its manufacturing transition and NovoSorb registrations remain significant areas for subsequent operational disclosure. The distinction between revenue, earnings and validated production capacity is central to assessing the company’s next reporting periods.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.